Biopharma
Asia Biopharma Manufacturing 2028
- Date
- 16–17 May 2028
- Location
- Singapore
Event information
- Date
- 16–17 May 2028
- Location
- Singapore
Overview
Asia-Pacific is strengthening its position as a major hub for biopharmaceutical manufacturing, driven by growing biologics pipelines, expanding production capacity and increasing investment in advanced manufacturing technologies. Across the region, manufacturers are adopting process intensification, automation, AI and digital technologies to improve productivity, flexibility and manufacturing resilience.
Singapore is one of Asia-Pacific's established biopharmaceutical manufacturing hubs, home to manufacturing operations from many of the world's leading biopharma companies. Continued investments in biologics, vaccines, ADCs and advanced manufacturing are further strengthening Singapore's role in the regional and global biopharmaceutical supply chain.
Taking place on 16–17 May 2028 in Singapore, Asia Biopharma Manufacturing 2028 will bring together biopharma manufacturers, biotech companies, CDMOs and technology providers from Singapore, South Korea, Japan, China, India, Southeast Asia, Australia and across the wider Asia-Pacific region.
The conference will explore the future of upstream and downstream processing, process intensification, analytical technologies and PAT, scale-up and technology transfer, AI and digital manufacturing, automation, advanced facilities and sustainable manufacturing — providing a focused platform to exchange expertise, discover new technologies and advance the next generation of biopharmaceutical manufacturing across APAC.
Programme
Day 1 — Tuesday 16 May 2028
- 08:30
Registration & Welcome Coffee
- 09:00
Chairperson's Welcome & Opening Remarks
- 09:10
SESSION I - APAC BIOPHARMA MANUFACTURING OUTLOOK & STRATEGY
- 10:25
Morning Networking Break & Exhibition Viewing
- 11:10
SESSION II: UPSTREAM PROCESSING & PROCESS INTENSIFICATION
- 12:25
Networking Lunch & Exhibition Viewing
- 13:40
SESSION III: DOWNSTREAM PROCESSING & PURIFICATION
- 14:55
Afternoon Networking Coffee & Exhibition Viewing
- 15:40
SESSION IV: ANALYTICAL DEVELOPMENT, PAT & QUALITY
- 17:00
End of Day 1 — Asia Biopharma Manufacturing 2028, Networking Reception
Day 2 — Wednesday 17 May 2028
- 09:10
SESSION V: SCALE-UP, MSAT & TECHNOLOGY TRANSFER
- 10:25
Morning Networking Break & Exhibition Viewing
- 11:10
SESSION VI: THE DIGITAL & AUTONOMOUS BIOPHARMA FACTORY
- 12:25
Networking Lunch & Exhibition Viewing
- 13:40
SESSION VII: FACILITIES, ENGINEERING & SUSTAINABLE MANUFACTURING
- 14:55
Afternoon Networking Coffee & Exhibition Viewing
- 15:40
SESSION VIII: MANUFACTURING EXCELLENCE, SUPPLY RESILIENCE & BIOPHARMA 2035
- 17:00
End of Conference
Who Attends
By Company Profile
- Biopharma & Big Pharma60%
- CDMO10%
- Solution & Service Providers25%
- Government, Research Institutes, Academia & Associations5%
By Job Function
- Manufacturing / Site Operations / Manufacturing Excellence22%
- Process Development / MSAT / Technology Transfer18%
- Upstream / Downstream Bioprocessing15%
- Analytical / CMC / Quality15%
- Engineering / Facilities / Automation / Digital15%
- Supply Chain / Procurement / External Manufacturing8%
- Business Development / Strategy / Other7%
By Country / Market
- Singapore25%
- South Korea & Japan20%
- China, Hong Kong & Taiwan20%
- Southeast Asia excluding Singapore15%
- India5%
- Australia & New Zealand5%
- US, Europe & other international10%
Want to Sponsor This Event?
Explore sponsorship opportunities and discover how your brand can connect with key decision-makers across the industry.
Speak with our Sponsorship Team
Register
Contact us for group bookings of three or more delegates.
| Delegate Category | Super Early Bird Rate Valid until 31st January 2028 | Early Bird Rate Valid until 31st March 2028 | Standard Rate |
|---|---|---|---|
| Biopharma, Big Pharma, Academics, Research Institutes & Government | SGD 699 | SGD 899 | SGD 1,099 |
| Service & Solution Provider | SGD 2,049 | SGD 2,249 | SGD 2,449 |
INSIGHTS
Read before you go
- BiopharmaMarket insight
Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?
Biologics manufacturing productivity depends on more than installed bioreactor volume. This article compares four 2,000 L single-use bioreactors with one 10,000 L stainless-steel reactor and examines how turnaround time, utilisation, titre, downstream capacity and manufacturing strategy can determine annual output.
Read more: Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor? - BiopharmaMarket insight
Stainless Steel vs Single-Use: Why Biomanufacturing Still Needs Both
Stainless steel and single-use systems serve different roles in modern biomanufacturing, with the right choice depending on production volume, product mix and demand certainty. This article examines how leading APAC facilities are combining scale, flexibility and resilience through steel, single-use and hybrid manufacturing strategies.
Read more: Stainless Steel vs Single-Use: Why Biomanufacturing Still Needs Both - BiopharmaMarket insight
Why Singapore Is Emerging as Biopharma’s China+1 Hub
Singapore’s biopharmaceutical sector is navigating short-term production volatility while strengthening its long-term position as a trusted bridge between China and Western markets. This article examines how Singapore’s regulatory credibility, advanced manufacturing ecosystem and geopolitical neutrality support its emerging role as a China+1 hub for global biopharma.
Read more: Why Singapore Is Emerging as Biopharma’s China+1 Hub


